23354-30-5

Basic information

• Product Name: 3-BROMO-5-HYDROXY-4-METHOXYBENZALDEHYDE
• Synonyms: 3-BROMO-5-HYDROXY-4-METHOXYBENZALDEHYDE;3-bromo-4-methoxy-5-hydroxybenzaldehyde
• CAS NO: 23354-30-5
• Molecular Formula: C₈H₇BrO₃
• Molecular Weight: 231.04
• Mol File: 23354-30-5.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-BROMO-5-HYDROXY-4-METHOXYBENZALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-BROMO-5-HYDROXY-4-METHOXYBENZALDEHYDE(23354-30-5)
• EPA Substance Registry System: 3-BROMO-5-HYDROXY-4-METHOXYBENZALDEHYDE(23354-30-5)

Safety Data

• Hazardous Substances Data: 23354-30-5(Hazardous Substances Data)

Upstream product

• 80547-72-4 acetic acid 5-formyl-2-methoxy-3-nitrophenyl ester 
• 186581-53-3 diazomethane 
• 16414-34-9 3-bromo-4,5-dihydroxybenzaldehyde 
• 2973-76-4 5-bromo-4-hydroxy-3-methoxybenzaldehyde 
• 74-88-4 methyl iodide 
• 621-59-0 isovanillin 
• 121-33-5 vanillin 
• 139-85-5 3,4-dihydroxybenzaldehyde 

Downstream Products

• 891148-72-4 C₁₉H₁₇BrO₇S 
• 6948-30-7 5-bromoveratralaldehyde 
• 1286210-10-3 C₂₅H₂₈O₃Si 
• 1286210-26-1 C₃₉H₄₂ClNO₆Si 
• 1286210-50-1 C₃₉H₄₀ClNO₆Si 
• 1286210-34-1 C₃₉H₄₂ClNO₆Si 
• 1286210-52-3 C₄₁H₄₄ClNO₇Si 
• 1286210-43-2 C₂₃H₂₅BrO₃Si 
• 1286210-20-5 C₂₄H₂₅BrO₃Si 
• 16414-34-9 3-bromo-4,5-dihydroxybenzaldehyde 
• 645-08-9 Isovanillic acid 
• 511257-19-5 2-benzyloxyimino-3-(4-{5-[2-benzyloxyimino-2-(2-{3-bromo-4-[3-bromo-5-(2-tert-butoxycarbonylamino-ethyl)-2-methoxy-phenoxy]-phenyl}-ethylcarbamoyl)-ethyl]-3-bromo-2-methoxy-phenoxy}-5-bromo-2-nitro-phenyl)-propionic acid pentafluorophenyl ester 
• 511257-18-4 2-[(E)-Benzyloxyimino]-3-(4-{5-[2-[(E)-benzyloxyimino]-2-(2-{3-bromo-4-[3-bromo-5-(2-tert-butoxycarbonylamino-ethyl)-2-methoxy-phenoxy]-phenyl}-ethylcarbamoyl)-ethyl]-3-bromo-2-methoxy-phenoxy}-5-bromo-2-nitro-phenyl)-propionic acid ethyl ester 

Relevant articles and documents

PYRIMIDONE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS AGAINST HIV INFECTED CELLS

The present disclosure is directed to pyrimidone derivatives of Formula I and their use for selectively killing HIV infected GAG-POL expressing cells without concomitant cytotoxicity to HIV nave cells, and for the treatment or prophylaxis of infection by HIV, or for the treatment, prophylaxis or delay in the onset or progression of AIDS or AIDS Related Complex (ARC).

Synthesis and antitumor activity of feruloyl and caffeoyl derivatives This paper is dedicated to Prof. Wei-xiao Hu for his lifelong commitment to mentoring graduate students

We developed two efficient protocols for the synthesis of feruloyl and caffeoyl derivatives from commercial vanillin and veratraldehyde. Pharmacological activities were assessed against a panel of human cancer cell lines in vitro. Most synthesized compounds demonstrated attractive cytotoxicity. Several new compounds demonstrated significant antiproliferative and cytotoxic activities against HeLa and Bewo tumor cell lines. In particular, 5-nitro caffeic adamantyl ester showed broad spectrum of tumor inhibition in 10 cell lines, and reduced tumor weight by 36.7% in vivo when administered at a dose of 40 mg kg-1.

Design, synthesis and biological evaluation of novel 4-hydroxybenzene acrylic acid derivatives

A series of 4-hydroxybenzene acrylic acid derivatives were designed and synthesized based on the ferulic acid of natural active ingredients. The tested compound 5a, 5f and 6a have significant anti-inflammatory activity with suppression rates of 45.29%, 44.75% and 24.11%, respectively, compared with that of indomethacin, and their cardiac toxicity was not observed. The structure-function relationship shows that the p-hydroxyl group on the α-position benzene ring, particularly if acetylated, contributes to the considerable anti-inflammatory activity; that the carboxyl group on the double bond, if esterified, also contributes to the anti-inflammatory activity; that the p-methylsulfonyl group on the other benzene ring, whose introduction is due to the COX-2 selectivity, also contributes to anti-inflammatory activity surprisingly.